Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

  • Carl Zeiss Meditec Inc.

May 2011
Carl Zeiss Meditec Inc. of Dublin, Calif., has announced that the Mel 80 excimer laser has received premarket approval for the treatment of hyperopia, or farsightedness, from the FDA. This hyperopia indication complements existing FDA-approved applications of the surgical laser for myopia and astigmatism, according to the company. It will allow the company to offer a broader range of treatment options to refractive surgeons and their patients. The device combines high-grade optics and advanced laser technology. Clinical results of the Mel 80 study for hyperopia were presented in March at the American Society of Cataract and Refractive Surgery in San Diego.

excimer laser
A rare-gas halide or rare-gas metal vapor laser emitting in the ultraviolet (126 to 558 nm) that operates on electronic transitions of molecules, up to that point diatomic, whose ground state is essentially repulsive. Excitation may be by E-beam or electric discharge. Lasing gases include ArCl, ArF, KrCl, KrF, XeCl and XeF.
A vision defect commonly referred to as farsightedness. Results when the image of a distant object is focused beyond the retina by the relaxed eye. The condition can be corrected by introducing a positive lens in front of the eye.
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2016 Photonics Media
x Subscribe to BioPhotonics magazine - FREE!